Why the study?
It was unknown whether circulating copeptin, proANP, and proADM levels are elevated in OSA and change with CPAP therapy to serve as proxies for diagnosis and treatment response.
Does continuous positive airway pressure therapy alter levels of copeptin, proANP, and proADM in patients with obstructive sleep apnea?
Does continuous positive airway pressure therapy alter levels of copeptin, proANP, and proADM in patients with obstructive sleep apnea?
Copeptin is associated with the presence of obstructive sleep apnea, while proANP and proADM levels may serve as biomarkers for acute and long-term responses to CPAP therapy, respectively.
These prohormones should not yet guide OSA diagnosis or CPAP monitoring; leaves open their potential as acute and chronic response markers.
STUDY OBJECTIVES: Obstructive sleep apnea (OSA) might lead to oxidative stress, inflammation and elevated circulating copeptin, proANP and proADM levels. We aimed to evaluate whether the levels of these prohormones are higher in patients with OSA and whether they might change under continuous positive airway pressure (CPAP) therapy, serving as potential proxies for the diagnosis and therapy-response in OSA. METHODS: A total of 310 patients with suspicion of OSA were recruited. Screening for OSA was performed using overnight pulse oximetry followed by polygraphy and a venous puncture in the morning. All patients diagnosed with OSA underwent CPAP adaptation. A venous puncture was conducted in the night before CPAP and in the following morning. At 1 and 6 months of treatment, polygraphy was performed, followed by a venous puncture in the morning. In the acquired blood, copeptin, proANP and proADM levels were measured. RESULTS: We analyzed 232 patients with OSA and 30 patients without OSA. Our results indicated that only copeptin levels differed significantly among patients with and without OSA at baseline. In OSA patients, the levels of proADM significantly changed after 1 and 6 months on CPAP therapy, when compared to baseline (p < 0.001 and p = 0.020). Additionally, proANP levels significantly decreased after 12 h on CPAP therapy, as compared to baseline levels (p < 0.001). CONCLUSIONS: Copeptin is significantly associated with the presence of OSA. ProANP levels might serve as a potential proxy for the acute response to non-invasive ventilation (12 h), while proADM reflects the long-term response (1 and 6 months).
No takes yet. Share an insight, caveat, or question.
Karakioulaki et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: